Full-Time
Proteomics instrument platform for NGPS sequencing
No salary listed
Remote in Canada
Remote
Remote role; travel 60-80%. Ideally located in Central or Western Canada.
Quantum-Si provides proteomics tools that analyze proteins at the single-molecule level using NGPS on a semiconductor chip. The workflow immobilizes peptides on a chip, uses fluorescent recognizers to read amino acids as they are cleaved, and delivers data through an end-to-end platform of benchtop instruments, consumables, and cloud software. It differentiates itself by combining semiconductor-based single-molecule proteomics with an integrated, easy-to-use platform and flexible financing that converts capital expenditures to operating expenses. Its goal is to speed up drug discovery and clinical diagnostics by enabling detailed profiling of proteoforms and post-translational modifications across research, pharma, and diagnostics labs.
Company Size
51-200
Company Stage
IPO
Headquarters
Guilford, Connecticut
Founded
2013
Help us improve and share your feedback! Did you find this helpful?
People at Quantum-Si who can refer or advise you
Health Insurance
401(k) Retirement Plan
401(k) Company Match
Real-time performance monitoring
Remote Work Options
Paid Vacation
Paid Holidays
Hybrid Work Options
Wellness Program
Mental Health Support
Gym Membership
Phone/Internet Stipend
Home Office Stipend
Quantum-Si reported 2025 revenue of $2.4 million and positioned 2026 as a "transition year" focused on developing its Proteus platform, targeting a late-2026 launch. The company ended 2025 with $215.8 million in cash. Management expects approximately $1 million revenue in 2026, with adjusted operating expenses capped at $98 million and cash usage at $93 million, sufficient to fund operations into Q2 2028. The company added 17 new placement customers in 2025 through an expanded instrument access programme. Quantum-Si is building a publication pipeline and developing new applications, including clinical proteomics and rapid pathogen detection, to drive consumable utilization. CEO Jeff Hawkins said the strategic focus on Proteus will enable a stronger commercial ramp from 2027 onwards.
Quantum-Si, a proteomics technology company, reported fourth quarter 2025 revenue of $451,000 and full-year revenue of $2.4 million. The company announced its next-generation Proteus platform will be priced at $425,000. For 2026, Quantum-Si provided conservative guidance of approximately $1 million in revenue, reflecting strategic decisions to support Proteus's launch. These include offering upgrade credits on current Platinum Pro system sales and continuing placement programmes, which will moderate near-term revenue but position the platform for stronger long-term adoption. The company reported a full-year 2025 net loss of $101.3 million, including $18.7 million in one-time litigation charges. Adjusted total operating expenses decreased to $86.3 million from $99 million year-over-year. Quantum-Si held $215.8 million in cash and investments as of December 31, 2025, providing runway into second quarter 2028.
QuantumSi is facing financial challenges, balancing capital raising efforts against poor revenue and ongoing losses. The company launched a $100 million at-the-market equity program on September 26, 2025, following a 12% weekly drop in share value. This strategy aims to provide financial flexibility with minimal shareholder dilution. Earlier, in July, QuantumSi raised $50 million through a direct placement, extending its operational runway.
Quantum-Si announces the launch of V4 sequencing kit, expanding proteome coverage and unlocking new applications for protein sequencing.
Quantum-Si (QSI) announced a securities purchase agreement with a single institutional investor for 29,940,119 shares of common stock at $1.67 per share, through a registered direct offering. This will result in gross proceeds of approximately $50 million, before deducting expenses. The offering is expected to close around July 8, 2025, pending customary conditions. A.G.P./Alliance Global Partners is the sole placement agent.